Molecular Testing in Breast Cancer

This article provides an overview of currently available molecular assays and testing modalities that have prognostic, predictive, and therapeutic value. These include multigene assays for invasive breast cancer (Oncotype DX, MammaPrint, Prosigna, and Breast Cancer Index) and ductal carcinoma in situ (Oncotype DX DCIS and DCISionRT) and companion tests to detect PIK3CA mutations and NTRK fusions.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Review Source Type: research

Related Links:

Bull Cancer. 2021 Oct 13:S0007-4551(21)00363-5. doi: 10.1016/j.bulcan.2021.06.017. Online ahead of print.ABSTRACTThe surgical management of breast cancer has been marked by a therapeutic de-escalation from radical surgery to breast conservation and from axillary curage to sentinel lymph node sampling. With regard to breast surgery, the de-escalation of treatment has been largely due to organized screening, which has made it possible to diagnose tumors of smaller volume or at an earlier stage. The indications for conservative surgery have been broadened by the addition of radiotherapy on one hand, and the introduction of ad...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: RSL is rapidly replacing WGL as the preoperative localization technique in breast surgery. This large nationwide registry study found no association between the type of localization technique and the odds of having a reoperation, thus confirming the results of previous prospective cohort studies.PMID:34642736 | DOI:10.1093/bjs/znab339
Source: The British Journal of Surgery - Category: Surgery Authors: Source Type: research
Int J Clin Oncol. 2021 Oct 7. doi: 10.1007/s10147-021-02036-1. Online ahead of print.ABSTRACTPURPOSE: Trials for DCIS have not explored whether outcomes for patients with large disease burden requiring mastectomy are comparable to those of patients with lumpectomy-amenable disease. We aim to identify whether patients with DCIS larger than 5 cm and diffuse-type DCIS differ in breast cancer mortality (BCM) from patients with disease less than 5 cm.METHODS: Patients diagnosed with DCIS in the SEER program were assessed to identify factors prognostic of breast-cancer-specific survival using competing risks regression.RESULTS: ...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractPurposeTrials for  DCIS have not explored whether outcomes for patients with large disease burden requiring mastectomy are comparable to those of patients with lumpectomy-amenable disease. We aim to identify whether patients with DCIS larger than 5 cm and diffuse-type DCIS differ in breast cancer mortality (BCM)  from patients with disease less than 5 cm.MethodsPatients diagnosed with DCIS in the SEER program were assessed to identify factors prognostic of breast-cancer-specific survival using competing risks regression.Results44,849 patients met criteria for the cumulative incidence e...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
J Clin Oncol. 2021 Oct 6:JCO2101896. doi: 10.1200/JCO.21.01896. Online ahead of print.ABSTRACTThe Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.PMID:34613792 | DO...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Ann Surg Oncol. 2021 Sep 28. doi: 10.1245/s10434-021-10847-9. Online ahead of print.ABSTRACTBACKGROUND: About 40 % of women with breast cancer achieve a pathologic complete response in the breast after neoadjuvant systemic treatment (NST). To identify these women, vacuum-assisted biopsy (VAB) was evaluated to facilitate risk-adaptive surgery. In confirmatory trials, the rates of missed residual cancer [false-negative rates (FNRs)] were unacceptably high (> 10%). This analysis aimed to improve the ability of VAB to exclude residual cancer in the breast reliably by identifying key characteristics of false-negative cases.M...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research
ConclusionAggressive BC subtypes occur among women with LFS. Surgical treatment, i.e. ME and CPM, may prolong time to a second BC diagnosis. Conclusion on long-term survival benefit is pending. Individual competing tumour risks and long-term outcomes need to be taken into consideration.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
Pathol Res Pract. 2021 Sep 22;227:153619. doi: 10.1016/j.prp.2021.153619. Online ahead of print.ABSTRACTBACKGROUND: HER2 was a recognized oncogene that promoted the development and metastasis of breast cancer, but its positive expression rate in invasive ductal carcinoma (IDC) was much lower than that in ductal carcinoma in situ (DCIS). The correlation between the occurrence and development of breast cancer and the amplification and overexpression of HER2 gene alone was still controversial. 14-3-3ζ had a strong protein binding ability and a variety of functions, mainly through the interaction with other proteins to ex...
Source: Pathology, Research and Practice - Category: Pathology Authors: Source Type: research
ConclusionsIn summary, high expression of C7 may promote breast cancer development and might be insensitive to TE-based chemotherapy. Our present study laid a foundation to help clinicians improve the identification of patients for TE-based chemotherapy by C7 in the era of precision medicine.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Non-surgical management of pure LN is safe, and the likelihood of requiring subsequent surgical excision or repeat CNB during follow-up is low. These data provide reassurance that routine excision of pure LN in the setting of radiologic-pathologic concordance is not required.PMID:34554341 | DOI:10.1245/s10434-021-10827-z
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Pathology